Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13676MR)

This product GTTS-WQ13676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13676MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4431MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ1244MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ4687MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ9207MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ12059MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ268MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ5106MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ10560MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW